With 0.73 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.34 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $35.8 whereas the lowest price it dropped to was $34.54. The 52-week range on SRRK shows that it touched its highest point at $46.98 and its lowest point at $6.76 during that stretch. It currently has a 1-year price target of $49.67. Beta for the stock currently stands at 0.49.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of SRRK was down-trending over the past week, with a drop of -0.92%, but this was up by 15.12% over a month. Three-month performance surged to 15.57% while six-month performance fell -17.91%. The stock lost -17.91% in the past year, while it has gained 365.01% so far this year. A look at the trailing 12-month EPS for SRRK yields -2.65 with Next year EPS estimates of -1.71. For the next quarter, that number is -0.68. This implies an EPS growth rate of -7.21% for this year and 35.59% for next year. EPS is expected to grow by 52.01% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -5.90%.
Float and Shares Shorts:
At present, 94.87 million SRRK shares are outstanding with a float of 72.50 million shares on hand for trading. On 2025-06-13, short shares totaled 14.93 million, which was 1573.0 higher than short shares on 1747267200. In addition to Mr. David L. Hallal as the firm’s CEO & Chairman of the Board, Mr. Mo Qatanani Ph.D. serves as its Chief Scientific Officer.
Institutional Ownership:
Through their ownership of 1.1863099 of SRRK’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-03-31, SRRK reported revenue of $0.0 and operating income of -$77090000.0. The EBITDA in the recently reported quarter was -$76697000.0 and diluted EPS was -$0.67.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for SRRK since 3 analysts follow the stock currently. There are 3 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With SRRK analysts setting a high price target of 57.0 and a low target of 45.0, the average target price over the next 12 months is 49.66667. Based on these targets, SRRK could surge 60.65% to reach the target high and rise by 26.83% to reach the target low. Reaching the average price target will result in a growth of 39.98% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$2.23838 being high and -$2.54954 being low. For SRRK, this leads to a yearly average estimate of -$2.42909.
